34 results about "Brain cancer" patented technology

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

The present invention relates to methods, compositions, and combinations for inhibiting the NLRP3 inflammasome and / or LON protease as well as methods, compositions, and combinations for treating cancer, particularly blood cancer or brain cancer. In certain aspects, the compositions and combinations include a synthetic triterpenoid, such as 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole (“CDDO-2P-Im”) and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole (“CDDO-3P-Im”).

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

The disclosure provides a liposome nanoparticle, a pharmaceutical composition comprising liposome nanoparticles, and a method of treating brain cancer. In some aspects, the liposome nanoparticle comprising a folate bearing lipid and nucleic acid molecules (e.g., siRNA or shRNA) that reduce the expression of H2.0 Like Homeobox (HLX). The liposome nanoparticle optionally comprises a diameter of about 50 nm to about 400 nm. In some aspects, the pharmaceutical composition comprises the liposome nanoparticles and a pharmaceutically acceptable carrier, diluent, or excipient. In some aspects, the method of treating brain cancer comprises administering to a subject in need thereof the liposome nanoparticle.

The present invention relates to a therapeutic composition from natural substances that targets cancer cells, specifically brain cancer cells, and to a method for preparing same, wherein the composition comprises: 1) a therapeutic agent extracted from black seed, in the form of thymoquinone and 2) between 238,671 and 1,500,000,000 platelets, wherein components (a) and (b) are dissolved in 1 mL blood plasma proteins.

To provide a method for treating a disease.SOLUTION: Tricyclic PARP1 inhibitors and pharmaceutical compositions comprising the inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a method for treating a subject in need of treatment of brain cancer, the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is brain penetrant.SELECTED DRAWING: None

The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and / or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and / or essential tremors are also disclosed.

The invention relates to a compound of formula (I), wherein, for example, - Z is representing a group (II), wherein R5 is representing NR6R7 group and wherein R6 and R7 represent independently a hydrogen - R4 is representing a O-aryl ring, - X is representing a NR2R3 group, wherein R2 and R3 are independently hydrogen and a (C1- C10)alkyl group, - R1 is representing a group (III), for its use in the prevention or the treatment of one of the following brain cancers chosen among: glioblastoma, astrocytoma, oligodendroglioma, medulloblastoma, ependymoma, meningioma, pineoblastoma, or in the prevention or the treatment of epilepsies or infantile epilepsies.

The present application describes various implementations of devices, systems, and methods for electrical treatment of cancer in the brain. The systems can include an implanted component with a hub and two flexible electrodes, wirelessly connectable to an external retriever for transmission of power and data. The systems may provide stimulation to and / or recording from the target brain tissue. Systems and methods for implantation of one or more components are also described. Such systems can include a center stylet, a hollow insertion needle, and an outer tube for releasably retaining the implanted electrode and hub during an insertion procedure.

The novel compounds, compositions, and methods disclosed herein are effective for treating subjects suspected of having or developing a condition, such as cancer (i.e., brain cancer or cancer that has metastasized to the brain). A method for treating cancer can include administering to a subject a pharmaceutical composition comprising at least one of the novel compounds disclosed herein, and optionally one or more additional anti-cancer therapies. The compounds, compositions, and methods can further be used for drug screening and other detection and isolation methods.

Methods for inhibiting, reducing, or stopping the growth of central nervous system cancers, such as brain tumors, or cancers influenced by the nervous system are described herein. The methods also include, in some instances, reducing or maintaining the size or volume of such cancers. Such methods are useful for treating and combatting aggressive brain cancers.

The novel compounds, compositions, and methods disclosed herein are effective for treating subjects suffering from or suspected of suffering from a health condition (e.g., cancer (i.e., brain cancer or cancer metastatic to the brain). Methods of treating cancer may comprise administering to a subject a pharmaceutical composition comprising at least one novel compound disclosed herein, and optionally more than one other anti-cancer therapy. These compounds, compositions, and methods may also be used in drug screening, as well as other detection and isolation methods.

Peptides of D-amino acids and their use in therapy, for example treating or preventing brain cancer, as well as pharmaceutical compositions comprising the peptides, the peptides being effective modulators of matrix metalloproteinases (MMPs).

The present invention relates to a method for preparing a melatonin-producing miniature pig cell line, and a use thereof. It has been confirmed that a miniature pig-derived pineal gland cell line of the present invention may be used as a pineal gland cell line by having a single-characteristic cell line isolated. In addition, it has been confirmed that, in the isolated pineal gland cell line, the pineal gland markers and melatonin synthesis proteins AANAT, ASMT, SAG, ADRB1, and SLC15A1 are expressed, and it has been confirmed that serotonin and melatonin secreted by pinealocytes are extracellularly secreted. In addition, it has been confirmed that the pineal gland cell line expresses pineal gland markers and proteins. In addition, it has been confirmed that, in a cell line in which the pineal gland cell line has MTNR1A marked with red fluorescence, fluorescence expression increases in a melatonin-dependent manner, and the fluorescence expression and MTNR1A are reduced due to a melatonin antagonist, and thus it has been confirmed that the present invention may be used for brain disease or brain cancer screening by using same.

Described herein is 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxolan-5-ol (Structure B), a small molecule splicing modulator (SMSM) of mRNA encoded by a gene, such as a pre-mRNA, for use in the treatment of neurological and neurodegenerative diseases, such as Huntington's disease and brain cancer.

There exist in NATURE a number of microscopic organisms that exhibit survival traits under extreme conditions. Several exhibit survival traits under extensive radiation fields. One such organism is Deinococcus Radiodurans. (refer to Refs 1 a and 1 b of PRIOR ART) We believe that this survival trait is genetically based. We claim that this genetic trait can be utilized for enhancement of radiation susceptibility and resistance and can be encapsulated in a pharmaceutical. This is partially confirmed in Ref 1c for a human cell system (refer to the PRIOR ART section), and justifies our Patent. We claim as our invention a pharmaceutical selectively utilizing the Deinococcus Radiodurans genes, and DNA / RNA genetic as well as chemical repair system, for the application to radiation treatment of human Glioblastoma Brain Cancer. We claim that we can utilize this pharmaceutical for the targeted enhancement of radiation susceptibility and resistance in the cancerous and healthy tissues, using energetic Protons or Carbon lons and the associated Bragg Peak selected energy deposition for these regions. We claim that this pharmaceutical can also be utilized with other focused radiation modalities such as X-Rays or electron beams, but not as effectively. We specifically select the DR1709 Deinococcus Radiodurans gene for this application and the DrRRA(DR2418) Deinococcus Radiodurans gene for this application. We do not exclude other Deinococcus Radiodurans genes, and DNA / RNA genetic as well as chemical repair systems not known at this time to this inventor currently or in the future. We do not exclude genes of other micro-organisms that survive under extreme conditions. However, only the application of radiation resistant micro-organism genetic material to create a pharmaceutical for the control of radiation resistance and susceptibility is being patented with a specific organism and gene set as the basis of this Patent (i.e., Deinococcus Radiodurans) and the application to the radiation treatment of human Glioblastoma Brain Cancer.

The present invention relates to a method for simultaneously producing two-dimensional brain cancer cells and three-dimensional brain cancer spheroids derived from a brain cancer individual. It has been confirmed that two-dimensional brain cancer cells can be obtained by extracting cancer tissue from a brain cancer individual, and three-dimensional brain cancer spheroids can be produced from brain tissue discarded in this process. That is, according to the present invention, since both two-dimensional brain cancer cells and three-dimensional brain cancer spheroids, which are two screening agents, can be produced from one sample, the economic effect is excellent, and all advantages of respective drug screening can be utilized. Therefore, it is expected that an effect of increasing the accuracy of drug screening can be achieved by minimizing the disadvantages of each method.

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

This disclosure relates to an oral dosage form (such as a capsule) comprising (a) mildametinib having a d90 of 250 microns or less, a d50 of 50 microns or less, or both, and (b) one or more pharmaceutically acceptable pharmaceutical excipients. Such dosage forms are useful in the treatment of tumors and cancers (such as plexus neurofibroma (PN), plexus neurofibroma associated with neurofibromatosis type 1 (NF1-PN), high-grade glioma (HGG), low-grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and cancers that have metastasized to the patient's brain). This disclosure also relates to improved dosage regimens for mildametinib treatment.

A composition containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery is provided, whereby upon intranasal administration, the MEVs travel through a specific pathway, via the olfactory nerve, through the lateral olfactory tract (LOT) to interconnected brain regions, and to specific regions within the brain. The MEVs are transported via neuronal axonal transport. The MEVs have the ability to cross synapses, including (i) synapses between olfactory nerve neurons (OSNs) and mitral / tufted neurons, (ii) synapses between mitral / tufted neurons and local neurons in various brain regions anchored by the lateral olfactory tract (LOT), and (iii) synapses between neurons in brain regions anchored by the LOT and neurons from the frontal cortex, hippocampus, thalamus, and hypothalamus. The composition contains microalgae (MEV)-derived extracellular vesicles loaded with a bioactive cargo for treating, detecting, diagnosing, or monitoring diseases, disorders, or conditions of or involving the brain, and specifically provides neuronal delivery of the cargo. The compositions and methods have a variety of applications as therapeutic and diagnostic agents for treating, diagnosing, and monitoring diseases, disorders, or conditions of or involving the brain. The compositions can be used in methods and uses for treating cancers involving the brain, for example, to deliver therapeutic agents for psychiatric diseases, disorders, and conditions, and to deliver therapeutic agents for neurodegenerative diseases, disorders, and conditions.

Compounds, compositions and methods effective for treating a subject having or suspected of developing a health condition, for example, cancer (i.e. brain cancer or a cancer metastasizing to the brain). The method of treating cancer can include administering a pharmaceutical composition to a subject. The composition may include least one of compound. Optionally, one or more additional anti-cancer therapies may be administered with the pharmaceutical composition. The compounds, compositions and methods can be further used for drug screening, detection and isolation.

Benzaza # imgabs0 # derivatives of formula (I), compositions comprising therapeutically effective amounts of these benzaza # imgabs1 # derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with central nervous system (CNS) disorders or associated with cognitive impairment risk factors. In particular, the present invention relates to the use of an alpha5-containing GABAA R agonist (e.g., an alpha5-containing GABAA R positive allosteric modulator) in the treatment of cognitive impairment associated with central nervous system (CNS) disorder or having a risk factor associated with cognitive impairment in a subject in need or at risk, the subjects include, but are not limited to, subjects having or at risk of age-related cognitive impairment, mild cognitive impairment (MCI), amnetic MCI (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), proactive AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), or the like. Cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X disorder, Rett syndrome, compulsive behavior and substance addiction associated with cancer treatment. The present invention also relates to the use of [alpha] 5-containing GABAA R agonists (e.g., [alpha] 5-containing GABAA R positive allosteric modulators), as described herein, in the treatment of brain cancer, including brain tumors, e.g., myeloblastoma, and cognitive impairment associated therewith. # imgabs2 #

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) midametinib having a d90 of not more than 250 microns, a d50 of not more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful for the treatment of tumors and cancers, such as plexus neurofibroma (PN), plexus neurofibroma associated with type 1 neurofibromatosis (NF1-PN), high-grade glioma (HGG), low-grade ovarian cancer, Langerhans cell tissue cell hyperplasia (LCH), brain cancer, and cancer that has metastatic to the brain of a patient. The present disclosure also relates to an improved dosage regimen for midametinib treatment.

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

The present invention relates to a method for preparing a melatonin-producing miniature pig cell line, and a use thereof. It has been confirmed that a miniature pig-derived pineal gland cell line of the present invention may be used as a pineal gland cell line by having a single-characteristic cell line isolated. In addition, it has been confirmed that, in the isolated pineal gland cell line, the pineal gland markers and melatonin synthesis proteins AANAT, ASMT, SAG, ADRB1, and SLC15A1 are expressed, and it has been confirmed that serotonin and melatonin secreted by pinealocytes are extracellularly secreted. In addition, it has been confirmed that the pineal gland cell line expresses pineal gland markers and proteins. In addition, it has been confirmed that, in a cell line in which the pineal gland cell line has MTNR1A marked with red fluorescence, fluorescence expression increases in a melatonin-dependent manner, and the fluorescence expression and MTNR1A are reduced due to a melatonin antagonist, and thus it has been confirmed that the present invention may be used for brain disease or brain cancer screening by using same.

The present invention relates to compounds, compositions, and methods for inhibiting RE1 silencing transcription factor (REST) ​​target genes. Specifically, peptides having the sequences TEDLEPPEPPLPKEN (SEQ ID NO: 1) and EDLEPPEPPLPK (SEQ ID NO: 15), or a reverse sequence (retroinverted, RI) consisting of the D-amino acids nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. These peptides can be used to treat, prevent, or alleviate diseases such as traumatic brain injury, epilepsy, dementia, Huntington's disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer, diabetes, and peripheral nerve damage.

Compounds, compositions and methods disclosed herein are effective for treating a subject having or suspected of developing a health condition, for example, cancer (i.e., brain cancer or a cancer metastasizing to the brain). The method of treating cancer can include administering a pharmaceutical composition to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one or more additional anti-cancer therapies. The compounds, compositions and methods can be further used for drug screening and other methods of detection and isolation.

Compositions comprising peptides that bind specifically to BΔg (deglycosylated brevican), and methods of use thereof to deliver therapeutic and diagnostic agents to brevican-expressing cells, e.g., cancerous cells, e.g., brain cancer cells, e.g., glioblastoma cells.